Is tepotinib on the market?

In March 2020, tepotinib was first approved in Japan for the treatment of MET-altered non-small cell lung cancer (NSCLC), and was subsequently approved by the U.S. Food and Drug Administration in February 2021. In February 2022, tepotinib was approved for use in Europe.

Tepotinib is the first oral MET-targeted tyrosine kinase inhibitor available in tablet and oral forms, allowing once-daily dosing of 450 mg, an advantage that may help reduce the drug burden typically associated with chemotherapy regimens. If a patient experiences certain side effects during use, the doctor may decide to reduce the dose to 225 mg once daily or interrupt or stop treatment with tepotinib. Common side effects include edema, nausea, low albumin levels in the blood, diarrhea, and increased creatinine levels in the blood.

The original drug of Tepotinib is a new type of drug that is not yet on the market in China and therefore has not been included in the medical insurance. The price of Tepotinib original drug specifications225mg*30 tablets per box listed overseas is around RMB 80,000 (the price may fluctuate due to the exchange rate). It has been on the market for a short time and is expensive. There are also Tepotinib generic drugs produced in other countries. The price of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 per box (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode Medical Consultant.